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Target predictionAbstract The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov) is a valuable data
resource focused on an increasing number of well-characterized cancer genomes. In part, TCGA
provides detailed information about cancer-dependent gene expression changes, including changes
in the expression of transcription-regulating microRNAs. We developed a web interface tool
MMiRNA-Tar (http://bioinf1.indstate.edu/MMiRNA-Tar) that can calculate and plot the
correlation of expression for mRNAmicroRNA pairs across samples or over a time course for a
list of pairs under different prediction conﬁdence cutoff criteria. Prediction conﬁdence was estab-
lished by requiring that the proposed mRNAmicroRNA pair appears in at least one of three target
prediction databases: TargetProﬁler, TargetScan, or miRanda. We have tested our MMiRNA-Tar
tool through analyzing 53 tumor and 11 normal samples of bladder urothelial carcinoma (BLCA)
datasets obtained from TCGA and identiﬁed 204 microRNAs. These microRNAs were correlated
with the mRNAs of ﬁve previously-reported bladder cancer risk genes and these selected pairs exhib-
ited correlations in opposite direction between the tumor and normal samples based on the cus-
tomized cutoff criterion of prediction. Furthermore, we have identiﬁed additional 496 genes (830
pairs) potentially targeted by 79 signiﬁcant microRNAs out of 204 using three cutoff criteria, i.e.,nces and
178 Genomics Proteomics Bioinformatics 13 (2015) 177–182false discovery rate (FDR) < 0.1, opposite correlation coefﬁcient between the tumor and normal
samples, and predicted by at least one of three target prediction databases. Therefore, MMiRNA-
Tar provides researchers a convenient tool to visualize the co-relationship between microRNAs
and mRNAs and to predict their targeting relationship. We believe that correlating expression
proﬁles for microRNAs and mRNAs offers a complementary approach for elucidating their
interactions.Introduction
MicroRNAs (miRNAs) are an abundant family type of non-
coding RNAs that participate in post-transcriptional regula-
tion [1] through binding to the 30 UTRs of mRNAs or target
genes. Mature miRNAs typically are 17–24 nucleotides in
length. Single-stranded mature miRNAs are generated from
miRNA precursors (pre-miRNA) by the RNase III type
enzyme Dicer in the cytoplasm [2].
There are many studies that demonstrate inverse correla-
tions in the expression of speciﬁc miRNAs and their corre-
sponding target mRNAs [3–6], although studies showing
positive correlations also exist [7,8]. Aberrant miRNA expres-
sion is involved in the pathogenesis of several human diseases
[9–11]. Interestingly, Miles et al [8] showed directional changes
in microRNA/mRNA positive and negative correlation
between the tumor and normal samples.
Urothelial carcinoma occurring in the bladder is the fourth
leading type of cancer in men and the ninth most common can-
cer in women, with 150,000 related deaths per year in the world
[12]. Many genes such as FGFR3, HRAS, RB1, TSC1, and
TP53, have been associated with bladder cancer [13–17].
Recurrent mutations in these genes have also been reported
in many studies [18,19].
The Cancer Genome Atlas (TCGA), a project initiated
by the National Cancer Institute (NCI) and the National
Human Genome Research Institute (NHGRI) of the United
States in 2006, continues to characterize and document a
number of tumor or cancer samples. So far, more than
10 cancer tissues (breast, central nervous system, endocrine,
gastrointestinal, gynecologic, head and neck, hematologic,
skin, soft tissue, thoracic, and urologic) have been
presented for potential study and their sequencing data
are currently accessible to researchers (http://cancergenome.
nih.gov).
Assuming that signiﬁcant correlations between miRNA
and mRNA expression levels in opposite directions
between the tumor and normal samples would tend to sig-
nal the existence of demonstrable targeting relationships,
we performed pairwise correlation calculations of miRNA
and mRNA expression proﬁles of both the tumor and
normal samples for the bladder urothelial carcinoma
(BLCA) datasets available from the TCGA project to pre-
dict targeting relationships between speciﬁc miRNAs and
mRNAs using MMiRNA-Tar, a tool developed in-house
by us. The results from global correlation analysis of the
expression data for miRNAs and mRNAs revealed poten-
tial targeting miRNAs for known bladder cancer risk
genes, as well as, additional cancer risk genes apparently
targeted by these miRNAs.Methods
Data source
The test datasets were downloaded from TCGA Data Portal
(https://tcga-data.nci.nih.gov/tcga/). The type of cancer
studied in this paper is bladder urothelial carcinoma (BLCA).
Illumina HiSeq data were acquired based on the availability of
expression proﬁle for both miRNA, which was produced by
Baylor College Human Genome Sequencing Center (BCGSC),
and mRNA, which was produced by University of North Car-
olina at Chapel Hill (UNC). Speciﬁcally, TCGA level 3
mRNASeq data were produced on Illumina HiSeq 2000
sequencers and its public release date is 04/30/2012. Read
counts and reads per kilobase per million (RPKM) per com-
posite gene (UCSC genes Dec 2009 build) were calculated
using the SeqWare framework via the RNASeqAlign-
mentBWA workﬂow (http://seqware.sourceforge.net). The
miRNA analyses of TCGA level 3 BLCA samples were pro-
duced by Illumina HiSeq as well. Normalized expression per
miRNA gene (Reads per million miRNA mapped or RPM)
was reported as miRNAs expression measurement unit. The
public release date of miRNA data used in this study is
10/09/2014. To make measurement units between two sequenc-
ing data sets consistent, we converted RPKM expression val-
ues for mRNA samples into transcripts per million (TPM)
values. A total of 53 tumor and 11 normal samples from seven
batches (batch No. 86, 113, 128, 150, 170, 175, and 192) were
downloaded and tested for both miRNA and mRNA data.
The normalized mRNA and miRNA expression data of both
the tumor and normal samples are shown in Tables S1 and
S2, respectively.
Data pre-processing
Expression proﬁles of BLCA datasets for a total of 20,532
mRNAs were downloaded. We excluded 29 genes that do
not have their gene symbols available (gene names marked
as ‘‘?’’ in the annotation table) from the list. We also excluded
SLC35E2 because it is doubly reported. Thus, a total of 20,501
genes were used to check against a miRNA expression ﬁle, in
which 1046 miRNAs were available.
Correlation coefﬁcient calculation and target prediction
Calculations of linear (positive) or inverse (negative) correla-
tion (Pearson correlation) for each miRNAmRNA pair
across samples and the prediction of miRNA and mRNA tar-
get relationship were implemented in C language. All three
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Figure 1 Workﬂow of selecting potential microRNAs and their gene targets
Liu Y et al / Correlation of mRNA and MicroRNAs 179databases including TargetProﬁler [20], TargetScan [21], and
miRanda [22] were precompiled for the search of targeting
relationship between miRNA and mRNA. We claimed the
existence of the targeting relationship if a target prediction
outcome is supported by at least one of the three databases
mentioned above. The FDR multiple testing [23] control and
normalization steps were implemented using a customized R
script.
Figure 1 shows the workﬂow of selecting potential targeting
miRNAs and additional targeted genes. MMiRNA-Tar is
available at http://bioinf1.indstate.edu/MMiRNA-Tar and
the software source code is freely available upon request for
non-commercial purposes.Results
Correlation of expression proﬁles of miRNAs and mRNAs
We took ﬁve genes that have been reported as common blad-
der cancer risk genes in multiple studies and the National Insti-
tutes of Health (NIH) Genetic Home Reference website
(http://ghr.nlm.nih.gov/condition/bladder-cancer) and set out
to identify their potential targeting miRNAs using three pop-
ular target prediction databases mentioned in the Method sec-
tion. These genes include FGFR3, HRAS, RB1, TSC1, and
TP53. We calculated correlations (Pearson correlation)
between each of the ﬁve genes and all miRNAs reported in
53 tumor and 11 normal samples from the aforementioned
TCGA datasets. We then selected the pairs with correlation
values in opposite directions between the tumor and normal
samples and with targeting relationship predicted by at leastone of three databases using MMiRNA-Tar. As shown in
Figure 2, three prediction databases showed similar density
distribution patterns for calculated correlation values in the
tumor samples, although the density distribution by miRanda
was slightly different from the other two in the normal sam-
ples. We concluded that requiring a prediction outcome from
any of these databases would be reasonable.
Using these ﬁve genes, 204 miRNAs in total were
obtained based on the cutoff criteria of opposite correla-
tion direction between the tumor and normal samples
and by at least one database prediction (Table 1 and
Table S3). These 204 miRNAs are presumed to have tar-
geting relationships with ﬁve bladder cancer risk genes.
The expression information in heatmap format for 204
miRNAs (259 pairs) across 53 tumor and 11 normal sam-
ples is shown in Figure S1. We noticed that miRNAs
targeting the same gene(s) were often grouped together
using hierarchical clustering with the Pearson correlation
distance measure method of multiple array viewer
(http://sourceforge.net/projects/mev-tm4/).
The expression proﬁle correlation analysis for 79 selected
miRNAs and their targeting mRNAs
We then calculated correlations and predicted targeting rela-
tionships for all possible pair combinations of 204 miRNAs
and 20,501 mRNAs in 53 tumor and 11 normal samples of
BLCA data. We obtained 830 additional miRNA–mRNA
pairs (comprising of 79 miRNAs and 496 genes) showing
opposite correlated relationships between the tumor and nor-
mal samples and having at least one database prediction out-
come with FDR< 0.1. Figure 3 is a Venn diagram showing
Figure 2 Density distribution of correlation of the ﬁve initial genes and their paired miRNAs for tumor and normal samples
Pearson correlation was calculated for all possible pair combinations of FGFR3, HRAS, RB1, TSC1, and TP53 and 1046 miRNAs listed
in the BLCA dataset downloaded from TCGA. Targeting relationship was then predicted using databases including TargetProﬁler,
TargetScan, and miRanda. The distribution of the miRNA–mRNA correlation values of the prediction results by three databases is
presented for tumor samples (A) and normal samples (B).
Table 1 Correlations between ﬁve selected bladder cancer risk genes and their predicted targeting microRNAs
Gene Chromosomal location No. of targeting miRNAs
Average diﬀerence of correlation
between tumor and normal samples
FGFR3 4p16.3 55 0.627199249
HRAS 11p15.5 10 0.714147948
RB1 13q14.2 41 0.417446885
TP53 17p13.1 31 0.327425407
TSC1 9q34 122 0.630901655
Note: Targeting relationship was predicted using Targetproﬁler, TargetScan, and miRanda. Average difference of Pearson correlation for each gene
was calculated for all miRNAmRNA pairs of the respective gene between the tumor and normal samples.
180 Genomics Proteomics Bioinformatics 13 (2015) 177–182prediction results derived by applying the three target predic-
tion database ﬁlters. The additional list of miRNA-gene target
pairs, along with their correlation values and target prediction
result using the aforementioned cutoff criteria, is shown in
Table S4. We noticed, among the 830 pairs, half of the genes
seem to have targeting relationships with at least two of the
79 identiﬁed miRNAs. Thus, in addition to the ﬁve initial
genes, we obtained another 496 genes having at least one pre-
dicted targeting relationship with 79 selected miRNAs.
Gene functional enrichment analysis
We searched the Database for Annotation, Visualization and
Integrated Discovery (DAVID) [24,25] for functional informa-
tion about the 496 genes with their predicted targeting miR-
NAs identiﬁed above. Enrichment of these genes was found
in several GO biological processes. Some of genes are involved
in chromatin remodeling complex, some of genes are
associated with cell cycle regulation, and some genes are
involved in protein kinase signaling pathways. These
biological processes (cell cycle regulation, kinase signaling,chromatin remodeling) are frequently dysregulated in
bladder cancer [26]. Genes associated with aforementioned
biological processes and their associated GO terms are shown
in Table 2.
Discussion
In this study, we computed the correlation coefﬁcients for all
available combinations of miRNA and mRNA pairs using
TCGA BLCA sequencing data. Performing multivariable cor-
relation analysis on a genome scale would be our future
research strategy. Under the assumption of an opposite corre-
lation of miRNA and mRNA (gene) expression levels between
the tumor and normal samples as an indicator for the
miRNA–mRNA target relationship, we used ﬁve previously
reported bladder cancer risk genes to obtain a list of 204 poten-
tial targeting miRNAs by applying several state-of-the-art tar-
get prediction algorithms. We then used this list of miRNAs to
identify other potential targeted pairs (genes), which could be
bladder cancer risk candidate genes, and perform GO
functional analysis on these genes. Fewer pairs with negative
TargetProfiler 
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Figure 3 Venn diagram of miRNA–mRNA pairs of BLCA dataset
predicted by difference databases
Correlation was calculated for all possible pair combinations of 204
miRNAs (targeting the initial ﬁve genes) and 20,501 mRNAs of the
BLCA dataset. Targeting relationship was predicted with the
criteria: (1) opposite correlation between the tumor and normal
samples, (2) prediction by at least one database of TargetProﬁler,
TargetScan, and miRanda, and (3) false discovery rate <0.1.
Table 2 Predicted target genes along with their associated GO terms
Gene
SHPRH, RSF1, MLL, NAP1L1, WRN, MLH3, SIRT1, TAF5L, HUWE1,
BRPF3, SUPT16H, PHF21A, KDM3B, PARP1, USP16, MYSM1, RERE,
EP400, APC
TAF5L, HUWE1, BRPF3, USP16, SIRT1, MYSM1, EP400
TAF5L, MLL, RSF1, HUWE1, BRPF3, PHF21A, KDM3B, USP16,
SIRT1, MYSM1, EP400, RERE
TAF5L, HUWE1, BRPF3, USP16, SIRT1, MYSM1, EP400
SHPRH, RSF1, MLL, NAP1L1, SIRT1, TAF5L, BRPF3, HUWE1,
SUPT16H, PHF21A, KDM3B, USP16, RERE, EP400, MYSM1
UHRF2, ZAK, SMAD3, PPP1CB, PTPN11, APC
BCAT1, TAF1, MLL, ZAK, SMAD3, MLH3, PPP1CB, TACC1, JMY,
CUL5, PSMC6, UHRF2, HSPA2, CASP8AP2, MAPK4, PTP4A1,
TUBE1, TNKS, MAPRE2, MAPRE1, USP16, DST, APC
BCAT1, TAF1, ZAK, SMAD3, MLH3, PPP1CB, JMY, CUL5, PSMC6,
HSPA2, TUBE1, MAPRE2, TNKS, MAPRE1, USP16, DST, APC
BCAT1, CUL5, PPP1CB
BCAT1, TAF1, CUL5, PPP1CB
BCAT1, TAF1, CUL5, PPP1CB
BCAT1, TAF1, PSMC6, CUL5, TNKS, MAPRE2, MAPRE1, USP16,
PPP1CB, APC
BCAT1, TAF1, CUL5, HSPA2, TNKS, MAPRE2, MAPRE1, MLH3,
USP16, PPP1CB, APC
TNIK, ZAK, MAPK8IP1
PHIP, UTP11L, EPHA7, GRB10, BAIAP2, SOCS7, RAF1, SOCS5,
PTPN11
TWSG1, SMAD9, ID1, SMAD5, SMAD3
Liu Y et al / Correlation of mRNA and MicroRNAs 181correlation were reported in tumor samples than in normal
samples, suggesting that these miRNAs possibly lose their
functions in tumor samples, under the assumption that
miRNAs often anti-correlate with their gene targets.
Target prediction tools employed in our study for
predicting miRNA targets likely contain false positives
since the intersection of the predictions by Targetproﬁler,
TargetScan, and miRanda are low (Figure 3). In our effort,
to identify more targets, further analysis with at least one
prediction selection criteria was performed.
Conclusion
We have developed a web-based tool, MMiRNA-Tar, to plot
the correlation relationships and to report target prediction
outcomes between miRNAs and mRNAs across multiple sam-
ples and time course data. We used the complete TCGA
BLCA dataset currently available to test the tool and identiﬁed
204 potential targeting miRNAs and many additional targeted
genes by 79 selected miRNAs. We believe our tool is the ﬁrst to
utilize miRNA and mRNA correlation plotting combined with
multiple target prediction tools for the analysis of miRNA
contributions to transcription regulation in cancer. Although
the current work was limited to BLCA, the tool developed in
this study should also be valuable for studies of functional
miRNAs for other cancer datasets as well. The future work
will be extended to enhance our web-based tool by incorporat-
ing the functionality of matching seed regions of miRNA to
the mRNA targets. We would also like to incorporate otherenriched
GO ID Biological process
0051276 Chromosome organization
0016570 Histone modiﬁcation
0016568 Chromatin modiﬁcation
0016569 Covalent chromatin modiﬁcation
0006325 Chromatin organization
0051726 Regulation of cell cycle
0007049 Cell cycle
0022402 Cell cycle process
0000082 G1/S transition of mitotic cell
cycle
0051329 Interphase of mitotic cell cycle
0051325 Interphase
0000278 Mitotic cell cycle
0022403 Cell cycle phase
0031098 Stress-activated protein kinase
signaling pathway
0007169 Transmembrane receptor protein
tyrosine kinase signaling
pathway
0007178 Transmembrane receptor protein
serine/threonine kinase signaling
pathway
182 Genomics Proteomics Bioinformatics 13 (2015) 177–182available TCGA cancer datasets and identify interesting signa-
tures of miRNA–mRNA pairs for other datasets as well. We
also plan to develop a visualization tool to present the relation-
ships between miRNAs and mRNAs for comparing tumor and
normal expression data sets.Authors’ contributions
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